Intravenous IgM-enriched immunoglobulins in critical COVID-19: a multicentre propensity-weighted cohort study중요한 COVID-19에서 정맥내 IgM이 풍부한 면역글로불린: 다기관 성향 가중 코호트 연구Multicenter Study Published on 2022-07-072022-09-12 Journal: Critical Care [Category] COVID19(2023년), SARS, 진단, [키워드] 30-Day mortality acute respiratory distress addition applied Characteristics clinical clinically Cohort cohort study Complication concerning confidence interval controls coronavirus disease COVID-19 COVID-19 patients Cox regression models Critical Critically ill Critically ill patient daily dose dose early administration Effect Efficacy high mortality ICU ICU Patients Immunoglobulin immunoglobulin M immunoglobulins Inflammatory intravenous laboratory-confirmed Lung injury mechanical ventilation mechanically ventilated Mortality multicentre overcome Patient Primary outcome randomization randomized clinical trials retrospective SARS-CoV-2 selection bia statistical significance statistically statistically significant difference subgroup analysis subgroups survival treated Treatment treatment regimen two group was performed Weighting with COVID-19 [DOI] 10.1186/s13054-022-04059-0 PMC 바로가기 [Article Type] Multicenter Study
Efficacy and safety of favipiravir plus interferon-beta versus lopinavir/ritonavir plus interferon-beta in moderately ill patients with COVID-19: A randomized clinical trialRandomized Controlled Trial Published on 2022-07-012022-10-05 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 임상, [키워드] Adverse adverse event adverse events Antiviral Antiviral agents clinical Combination combination regimen combination therapy COVID-19 Day demonstrated Efficacy Efficacy and safety event examined Favipiravir FVP group groups hospital ICU admission ill patient in-hospital mortality incidence interferon Interferon-beta IQR LOS median Mild not different not significantly different Patient Potential treatment primary endpoint randomization Randomized randomized clinical trial Randomly receive Registered registry SARS-coronavirus SARS-CoV-2 Seven single-center Treatment treatment regimen Trial viral clearance [DOI] 10.1002/jmv.27724 PMC 바로가기 [Article Type] Randomized Controlled Trial
Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled TrialRandomized Controlled Trial Published on 2022-07-012022-10-05 Journal: Chest [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 28-day mortality activity acute respiratory symptom adjusted odds ratio adults hospitalized analyzed anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody assigned blinded clinical clinical status clinical trial convalescent plasma convalescent plasma group COVID-19 death died discharged Efficacy groups highest hospital Illness severity improve clinical outcomes lowest multicenter multivariable Neutralizing not differ outcome outcomes passive immunity Patient Placebo placebo group placebo-controlled plasma primary analysis Primary outcome randomization randomized clinical trial randomized patients Randomly receive Registration Regression model Result SARS-CoV-2 SARS-COV-2 infection Secondary analyses selected seronegative seven-category ordinal scale stratified supported the placebo group Treatment treatments for COVID-19 Trial trial participant with COVID-19 [DOI] 10.1016/j.chest.2022.06.029 [Article Type] Randomized Controlled Trial
Patients’ Perspectives on Emergency Department COVID-19 Vaccination and Vaccination Messaging Through Randomized VignettesRandomized Controlled Trial Published on 2022-07-012022-10-04 Journal: Public health reports (Washington, D.C. : 1974) [Category] 임상, [키워드] 95% CI age approach black Boston Care center Cincinnati Community conducted COVID-19 COVID-19 pandemic COVID-19 vaccination COVID-19 vaccine cross-sectional survey Department Emergency emergency department female had no Health highest hospital hypothetical Influenza Intention multisite offer outcome participant Participants Patient patient population patients preventive intervention randomization Randomized receive the vaccine university vaccination Vaccine Vaccine hesitancy vaccine-hesitant [DOI] 10.1177/00333549221085580 PMC 바로가기 [Article Type] Randomized Controlled Trial
Randomized double-blind placebo-controlled proof-of-concept trial of resveratrol for outpatient treatment of mild coronavirus disease (COVID-19)Randomized Controlled Trial Published on 2022-06-292022-10-05 Journal: Scientific Reports [Category] COVID19(2023년), SARS, 임상, 치료기술, 치료법, 치료제, [키워드] 95% CI adverse event age anti-inflammatory property Anti-viral ARMS assigned chose clinically coronavirus disease COVID-19 demonstrated determine double-blind Effect FDA female group Hospitalization incidence IND measure Mild mitigate one patient outcome Outpatient participant Patient Phase 2 study Placebo placebo-controlled Pneumonia primary outcome measure randomization Randomly receive recruited resveratrol single dose small sample size statistically Symptom treated Treatment Trial Vitamin D3 was determined was used [DOI] 10.1038/s41598-022-13920-9 PMC 바로가기 [Article Type] Randomized Controlled Trial
Dnah9 mutant mice and organoid models recapitulate the clinical features of patients with PCD and provide an excellent platform for drug screening Research Published on 2022-06-212022-10-05 Journal: Cell Death & Disease [Category] 변종, [키워드] affected airway Analysis Arm Bioinformatic can be used cause caused ciliary clinical feature co-immunoprecipitation demonstrated DNAH9 drug Drug screening etiology expression feature functional genetic disease identify Immune cell infiltration infections lack lung failure Lung function mice mimicking mutant Mutation outcome Pathogenesis Patient patients performed Phenotypes platform Protein protein levels randomization Respiratory tract infections responsible shown the patient Therapies western blot Western blot analysis [DOI] 10.1038/s41419-022-05010-5 [Article Type] Research
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]건강한 개인에서 다양한 COVID-19 백신 조합의 안전성 및 면역원성 평가: 무작위, 피험자 맹검, 대조 3상 시험을 위한 연구 프로토콜 [PRIBIVAC]Article Published on 2022-06-162022-09-11 Journal: Trials [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] adverse event adverse events anti-SARS-CoV-2 antibodies antibody approval best blood sample Blood samples BNT162b2 boost booster booster dose booster vaccinations cellular Cellular immune response collected Combination Comprehensive control arm Controlled clinical trial CoronaVac country COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines demonstration different time point different time points dose Effectiveness Eligible participants Endpoint enrolment evade excluded group healthy Heterologous homologous host immunity humoral immune immune profiling immune response Immunity Immunocompromised immunogenicity Immunoglobulin immunoglobulins Inactivated vaccine Infection Intervention intervention arm Laboratory test Laboratory tests Local maintain mRNA mRNA vaccine mRNA-1273 omicron over parameters participant performed persistence phase Phase 3 phase 3 trial physical population immunity pregnant primary endpoint Probability quantity raising randomization Randomized Randomized controlled trial regimen Regulatory SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event Serious Adverse Events Singapore Study protocol vaccination Vaccine vaccine availability vaccine booster vaccine candidate variants variants of concern volunteers wildtype [DOI] 10.1186/s13063-022-06345-2 PMC 바로가기 [Article Type] Article
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19Covid-19 예방을 위한 근육주사 AZD7442(Tixagevimab-Cilgavimab)Clinical Trial Published on 2022-06-092022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 비임상, 신약개발, 임상, 진단, 치료제, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adverse event adverse events age animal models assigned AstraZeneca breath cilgavimab Combination composed conducted coronavirus coronavirus disease Coronavirus disease 2019 Critical death dose Efficacy efficacy end point end point enrolled exposure to Follow-up Human incidence increased risk intramuscular injections median Mild moderate Neutralizing antibodies neutralizing antibody occurred participant pharmacokinetic data phase 3 trial Placebo placebo group prevention primary analysis Prophylactic randomization Randomized Randomly receive Relative risk reported respiratory response to vaccination risk reduction saline placebo SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severity shown single dose symptomatic COVID-19 the placebo group therapeutic effect Tixagevimab [DOI] 10.1056/NEJMoa2116620 PMC 바로가기 [Article Type] Clinical Trial
Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)Research article Published on 2022-06-012022-10-05 Journal: The Lancet Regional Health - Americas [Category] 임상, 치료법, [키워드] 95%CI acute lung injury allergic Analysis Antibody titer assigned Bayesian Bayesian framework benefit clinical benefits Clinical improvement clinical trial Combination conducted Controlled clinical trial convalescent plasma COVID-19 COVID-19 progression death Efficacy and safety eligible enrolled evaluate experimental group finding funding hospital hospitalized patient hospitals Innovation intention-to-treat population Interim interquartile range intravenous mean difference median titer Mild multicenter neutralizing antibody no evidence of Open-label Patient performed Plasma transfusion positive RT-PCR Prevent Primary outcome randomization Randomized randomized trial Randomly receive Registered SARS-CoV-2 SARS-CoV2 Science Severe case severe COVID-19 severe COVID-19 patient SOC Standard of care stratified Supportive treatment symptom onset technology the WHO Treatment Volume [DOI] 10.1016/j.lana.2022.100216 [Article Type] Research article
High-dose versus standard-dose vitamin D supplementation in older adults with COVID-19 (COVIT-TRIAL): A multicenter, open-label, randomized controlled superiority trialRandomized Controlled Trial Published on 2022-05-312022-10-04 Journal: PLoS Medicine [Category] COVID19(2023년), SARS, 임상, [키워드] adjusted hazard ratio Administered administration adverse effect age anti-infective drugs baseline benefit cancers conducted confidence interval contraindication coronavirus 2 COVID-19 criteria death delirium diagnosis of COVID-19 diarrhea died early administration eligibility eligibility criteria eligible France High dose High-dose high-dose group hospital Hospitalization ICU improves intention-to-treat population investigator involved IQR less limitation Local median age medical supervision Mortality multicenter observational studies Older older patient Open-label open-label design Organ failure outcome overall mortality oxygen Oxygen requirement paO2/fiO2 participant Patient Primary outcome Prognostic factor protective effect randomization Randomized Randomized controlled trial Randomly RCT respiratory risk factor Safety Monitoring Board SARS-CoV-2 SARS-COV-2 infection Sex SpO2 Standard dose Standard-dose steering committee survival sustained treat Treatment Trial use of antibiotics Vitamin D Vitamin D supplementation vitamin D supplements were assessed with COVID-19 women worsening [DOI] 10.1371/journal.pmed.1003999 PMC 바로가기 [Article Type] Randomized Controlled Trial